Hologic, Inc.

Symbol: HOLX

NASDAQ

75.75

USD

Market price today

  • 38.3037

    P/E Ratio

  • -0.5958

    PEG Ratio

  • 17.68B

    MRK Cap

  • 0.00%

    DIV Yield

Hologic, Inc. (HOLX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.50%

Operating Profit Margin

0.15%

Net Profit Margin

0.12%

Return on Assets

0.05%

Return on Equity

0.09%

Return on Capital Employed

0.07%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO:Mr. Stephen P. MacMillan
Full-time employees:6990
City:Marlborough
Address:250 Campus Drive
IPO:1990-03-01
CIK:0000859737

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.504% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.145%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.118%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.054% return, is a testament to Hologic, Inc.'s adeptness in optimizing resource deployment. Hologic, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.095%. Furthermore, the proficiency of Hologic, Inc. in capital utilization is underscored by a remarkable 0.074% return on capital employed.

Stock Prices

Hologic, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $77.25, while its low point bottomed out at $75.38. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Hologic, Inc.'s stock market.

Liquidity Ratios

Analyzing HOLX liquidity ratios reveals its financial health of the firm. The current ratio of 396.89% gauges short-term asset coverage for liabilities. The quick ratio (296.16%) assesses immediate liquidity, while the cash ratio (228.37%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio396.89%
Quick Ratio296.16%
Cash Ratio228.37%

Profitability Ratios

HOLX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 14.15% underscores its earnings before tax deductions. The effective tax rate stands at 16.77%, revealing its tax efficiency. The net income per EBT, 83.23%, and the EBT per EBIT, 97.41%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 14.53%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin14.15%
Effective Tax Rate16.77%
Net Income per EBT83.23%
EBT per EBIT97.41%
EBIT per Revenue14.53%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.97, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations. Meanwhile, a 2 cash conversion cycle and 612.05% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding296
Days of Inventory Outstanding121
Operating Cycle180.36
Days of Payables Outstanding38
Cash Conversion Cycle143
Receivables Turnover6.12
Payables Turnover9.69
Inventory Turnover3.02
Fixed Asset Turnover7.55
Asset Turnover0.45

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 4.68, and free cash flow per share, 4.02, depict cash generation on a per-share basis. The cash per share value, 9.24, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.28, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share4.68
Free Cash Flow per Share4.02
Cash per Share9.24
Operating Cash Flow Sales Ratio0.28
Free Cash Flow to Operating Cash Flow Ratio0.86
Cash Flow Coverage Ratio0.43
Short Term Coverage Ratio27.19
Capital Expenditure Coverage Ratio7.12
Dividend Paid and Capex Coverage Ratio7.12

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 29.32%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.53, we discern the balance between debt and equity financing. The long-term debt to capitalization, 34.17%, and total debt to capitalization, 34.53%, ratios shed light on its capital structure. An interest coverage of 5.04 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio29.32%
Debt Equity Ratio0.53
Long Term Debt to Capitalization34.17%
Total Debt to Capitalization34.53%
Interest Coverage5.04
Cash Flow to Debt Ratio0.43
Company Equity Multiplier1.80

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 16.33, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1.85, reflects the portion of profit attributed to each share. The book value per share, 20.33, represents the net asset value distributed per share, while the tangible book value per share, 3.43, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share16.33
Net Income Per Share1.85
Book Value Per Share20.33
Tangible Book Value Per Share3.43
Shareholders Equity Per Share20.33
Interest Debt Per Share11.87
Capex Per Share-0.61

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -17.12%, indicates top-line expansion, while the gross profit growth, -30.89%, reveals profitability trends. EBIT growth, -59.25%, and operating income growth, -59.25%, offer insights into operational profitability progression. The net income growth, -64.98%, showcases bottom-line expansion, and the EPS growth, -64.29%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-17.12%
Gross Profit Growth-30.89%
EBIT Growth-59.25%
Operating Income Growth-59.25%
Net Income Growth-64.98%
EPS Growth-64.29%
EPS Diluted Growth-64.33%
Weighted Average Shares Growth-1.89%
Weighted Average Shares Diluted Growth-1.98%
Operating Cash Flow Growth-50.55%
Free Cash Flow Growth-54.92%
10-Year Revenue Growth per Share76.09%
5-Year Revenue Growth per Share39.63%
3-Year Revenue Growth per Share13.63%
10-Year Operating CF Growth per Share131.79%
5-Year Operating CF Growth per Share59.90%
3-Year Operating CF Growth per Share24.82%
10-Year Net Income Growth per Share142.34%
5-Year Net Income Growth per Share556.74%
3-Year Net Income Growth per Share-56.47%
10-Year Shareholders Equity Growth per Share181.37%
5-Year Shareholders Equity Growth per Share130.27%
3-Year Shareholders Equity Growth per Share97.44%
Receivables Growth1.30%
Inventory Growth-0.98%
Asset Growth0.75%
Book Value per Share Growth4.87%
Debt Growth-0.18%
R&D Expense Growth3.85%
SGA Expenses Growth-4.86%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 17,221,676,800, captures the company's total value, considering both debt and equity. Income quality, 2.31, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.10, gauges operational efficiency, while the research and development to revenue, 7.30%, highlights investment in innovation. The ratio of intangibles to total assets, 45.63%, indicates the value of non-physical assets, and capex to operating cash flow, -14.29%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value17,221,676,800
Income Quality2.31
Sales General and Administrative to Revenue0.10
Research and Development to Revenue7.30%
Intangibles to Total Assets45.63%
Capex to Operating Cash Flow-14.29%
Capex to Revenue-3.73%
Capex to Depreciation-46.44%
Stock-Based Compensation to Revenue1.97%
Graham Number29.07
Return on Tangible Assets9.18%
Graham Net Net-2.45
Working Capital2,977,200,000
Tangible Asset Value847,000,000
Net Current Asset Value62,100,000
Invested Capital1
Average Receivables621,600,000
Average Payables455,300,000
Average Inventory620,650,000
Days Sales Outstanding57
Days Payables Outstanding133
Days of Inventory On Hand115
ROIC5.75%
ROE0.09%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.69, and the price to book ratio, 3.69, reflect the market's valuation relative to the company's book value. The price to sales ratio, 4.46, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 18.63, and price to operating cash flows, 16.19, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.69
Price to Book Ratio3.69
Price to Sales Ratio4.46
Price Cash Flow Ratio16.19
Price Earnings to Growth Ratio-0.60
Enterprise Value Multiple17.50
Price Fair Value3.69
Price to Operating Cash Flow Ratio16.19
Price to Free Cash Flows Ratio18.63
Price to Tangible Book Ratio3.41
Enterprise Value to Sales4.27
Enterprise Value Over EBITDA14.31
EV to Operating Cash Flow16.38
Earnings Yield2.66%
Free Cash Flow Yield5.26%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Hologic, Inc. (HOLX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 38.304 in 2024.

What is the ticker symbol of Hologic, Inc. stock?

The ticker symbol of Hologic, Inc. stock is HOLX.

What is company IPO date?

IPO date of Hologic, Inc. is 1990-03-01.

What is company current share price?

Current share price is 75.750 USD.

What is stock market cap today?

The market cap of stock today is 17678307750.000.

What is PEG ratio in 2024?

The current -0.596 is -0.596 in 2024.

What is the number of employees in 2024?

In 2024 the company has 6990.